Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance

Stock Track

Feb 25

TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.

The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.

TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1192984784"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192984784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192984784?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192984784","market":"nz","top_or_hot":-1,"title":"Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance","media":"Stock Track","content":"<p>TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.</p><p>TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 05:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.</p><p>TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"","article_id":"1192984784","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192984784","pubTimestamp":1771968831,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.The company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"个股追踪|TransMedics盘后飙升8.86%，得益于强劲的Q4业绩和乐观的指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}